Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) have been given a consensus recommendation of “Buy” by the twelve brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $28.50.

A number of analysts have commented on the company. Cantor Fitzgerald lifted their price target on Abeona Therapeutics from $21.00 to $34.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 11th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target (up previously from $20.00) on shares of Abeona Therapeutics in a research report on Monday, October 9th. Citigroup assumed coverage on Abeona Therapeutics in a research report on Tuesday, October 10th. They set a “buy” rating and a $32.00 price target for the company. ValuEngine cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Zacks Investment Research cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 23rd.

Shares of Abeona Therapeutics (NASDAQ:ABEO) traded up $0.05 during mid-day trading on Tuesday, reaching $14.60. The company had a trading volume of 422,169 shares, compared to its average volume of 468,649. Abeona Therapeutics has a 1 year low of $4.50 and a 1 year high of $22.75. The stock has a market cap of $682.92, a P/E ratio of -22.12 and a beta of 2.21.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. The company had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.22 million. research analysts predict that Abeona Therapeutics will post -0.6 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Rhumbline Advisers acquired a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $190,000. Wells Fargo & Company MN lifted its holdings in shares of Abeona Therapeutics by 3,421.8% in the 3rd quarter. Wells Fargo & Company MN now owns 35,218 shares of the biopharmaceutical company’s stock valued at $600,000 after buying an additional 34,218 shares during the period. Family Management Corp lifted its holdings in shares of Abeona Therapeutics by 50.0% in the 3rd quarter. Family Management Corp now owns 36,000 shares of the biopharmaceutical company’s stock valued at $614,000 after buying an additional 12,000 shares during the period. Schwab Charles Investment Management Inc. acquired a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $264,000. Finally, California State Teachers Retirement System acquired a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $275,000. 41.95% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Abeona Therapeutics Inc (ABEO) Receives Average Rating of “Buy” from Analysts” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/01/21/abeona-therapeutics-inc-abeo-receives-average-rating-of-buy-from-analysts.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.